Journal
JOURNAL OF CLINICAL MEDICINE
Volume 10, Issue 15, Pages -Publisher
MDPI
DOI: 10.3390/jcm10153392
Keywords
liquid biopsy; GALAD; PDGFR beta; liver cancer; biomarker; cirrhosis
Categories
Funding
- Federal Ministry of Education and Research (BMBF)
- German Research Foundation (DFG) [SFB/TRR 296, CRC1382, Ta434/3-1, Ta434/5-1]
Ask authors/readers for more resources
The study introduces a novel serological scoring tool, the APAC score, which consists of age, sPDGFR beta, AFP, and creatinine, and can identify HCC patients in cirrhotic population with high accuracy. The APAC score outperforms the GALAD score and is independent of disease etiology, including alcohol, viral infection, and NAFLD.
(1) Background: Surveillance of at-risk patients for hepatocellular carcinoma (HCC) is highly necessary, as curative treatment options are only feasible in early disease stages. However, to date, screening of patients with liver cirrhosis for HCC mostly relies on suboptimal ultrasound-mediated evaluation and alpha-fetoprotein (AFP) measurement. Therefore, we sought to develop a novel and blood-based scoring tool for the identification of early-stage HCC. (2) Methods: Serum samples from 267 patients with liver cirrhosis, including 122 patients with HCC and 145 without, were collected. Expression levels of soluble platelet-derived growth factor receptor beta (sPDGFR beta) and routine clinical parameters were evaluated, and then utilized in logistic regression analysis. (3) Results: We developed a novel serological scoring tool, the APAC score, consisting of the parameters age, sPDGFR beta, AFP, and creatinine, which identified patients with HCC in a cirrhotic population with an AUC of 0.9503, which was significantly better than the GALAD score (AUC: 0.9000, p = 0.0031). Moreover, the diagnostic accuracy of the APAC score was independent of disease etiology, including alcohol (AUC: 0.9317), viral infection (AUC: 0.9561), and NAFLD (AUC: 0.9545). For the detection of patients with (very) early (BCLC 0/A) HCC stage or within Milan criteria, the APAC score achieved an AUC of 0.9317 (sensitivity: 85.2%, specificity: 89.2%) and 0.9488 (sensitivity: 91.1%, specificity 85.3%), respectively. (4) Conclusions: The APAC score is a novel and highly accurate serological tool for the identification of HCC, especially for early stages. It is superior to the currently proposed blood-based algorithms, and has the potential to improve surveillance of the at-risk population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available